Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 19, 2010, Pages 5787-5792

  Swann, Steven L ^a   Merta, Philip J ^a   Kifle, Lemma ^a   Groebe, Duncan ^a   Sarris, Kathy ^a   Hajduk, Philip J ^a   Sun, Chaohong ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

DFG out; Kinase; p38; Switch pocket

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE; DORAMAPIMOD; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 14;

ARTICLE; BINDING KINETICS; BIOCHEMISTRY; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

ADENOSINE TRIPHOSPHATE; BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; KINETICS; MITOGEN-ACTIVATED PROTEIN KINASE 14; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77957595657     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.097     Document Type: Article

References (13)

1. K. Ono, and J. Han Cell. Signalling 12 2000 1
2. C. Pargellis, L. Tong, L. Churchill, P.F. Cirillo, T. Gilmore, A.G. Graham, P.M. Grob, E.R. Hickey, N. Moss, S. Pav, and J. Regan Nat. Struct. Biol. 9 2002 268
3. C.W. Lindsley, S. Barnett, M. Yaroschak, M.T. Bilodeau, and M.E. Layton Curr. Top. Med. Chem. 7 2007 1349
4. S. Kumar, J. Boehm, and J.C. Lee Nat. Rev. Drug Disc. 2 2003 717
5. C. Dominguez, D.A. Powers, and N. Tamayo Curr. Opin. Drug Disc. Dev. 8 2005 421
6. M.C. Genovese Arthritis Rheum. 60 2009 317
7. S.B. Cohen, T.T. Cheng, V. Chindalore, N. Damjanov, R. Burgos-Vargas, P. Delora, K. Zimany, H. Travers, and J.P. Caulfield Arthritis Rheum. 60 2009 335
8. (a) Flynn, D. L.; Petillo, P. A. WO2007/008917
9. (b) Flynn, D. L.; Petillo, P. A. WO2007/008917
10. (c) Flynn, D. L., Petillo, P. A. WO 2008/0248548
11. i]).
12. J. Regan, C.A. Pargellis, P.F. Cirillo, T. Gilmore, E.R. Hickey, G.W. Peet, A. Proto, A. Swinamer, and N. Moss Bioorg. Med. Chem. Lett. 13 2003 3101
13. Reagents and conditions: (a) pivaloyl cyanide, A., EtOH, 81%; (b) 1-isocyanatonaphthalene, pyridine, THF, 82%; (c) HATU, DIEA, DMA, amine.